Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

Completed · Phase 1

Conditions studied: Pneumococcal Infections

In brief

This Phase 1b will describe the safety and immunogenicity of 2 multivalent pneumococcal conjugate vaccine formulations in healthy Japanese adults in the United States.

Key facts

Study ID

NCT03642847

Run by

Pfizer

People needed

104

Starts

2018-08-29

Expected to finish

2019-03-29

Last updated by the study team

2019-06-12

Who can join

Age: 18 and older, up to 49. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female Japanese subjects 18 to 49 years of age, defined as Japanese born in Japan, with both parents and 4 grandparents who wer born in Japan (family tree by history), and who have not lived outside of Japan for more than 5 years total (confirmed by passport or interview)

You may not qualify if…

• Participation in other studies involving investigational drug(s), investigational vaccines, or investigational medical devised within 28 days prior to study entry and/or during study participation. Participation in purely observational studies is acceptable.

Where it is running

• Collaborative Neuroscience Network, LLC. — Garden Grove, California, United States
• Collaborative Neuroscience Network, LLC. — Long Beach, California, United States
• East-West Medical Research Institute — Honolulu, Hawaii, United States
• Clinilabs Drug Development Corporation — Eatontown, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.